A male newborn infant was recognized having Fanconi-Bickel syndrome (FBS) in the neonatal period. The presenting clinical findings were hyperglycemia and polyuria detected during an episode of acute enteritis. Physical examination was normal, biochemical analyses were suggestive of FBS: glycosuria, proteinuria, phosphaturia, generalized aminoaciduria, and increased levels of urinary b2-microglobulin, serum glucose and serum alkaline phosphatase. The molecular genetic analysis showed homozygosity for mutations within the gene of the glucose transporter 2 (Glut 2), 1213 C>T. The patient demonstrated improved clinical and metabolic status following institution of diet with frequent small meals and galactose-freemilk as well as pharmacological treatment with phosphate and vitamin a-OH-D3. In conclusion, infants showing hyperglycemia and polyuria may be considered having FBS also in the neonatal period. Early institution of adequate caloric intake and replacement of electrolytes and vitamin D may avoid or reduce metabolic complications.
INTRODUCTION
The Fanconi-Bickel syndrome (FBS), originally described in 1949, is a rare, well-defined clinical entity that is inherited in an autosomal recessive mode. It is characterized by hepatorenal glycogen accumulation, fasting hypoglycemia as well as postprandial hyperglycemia and hypergalactosemia, proximal renal tubular dysfuction, rickets and markedly stunted growth. The carbohydrate abnormalities indicate impaired utilization of two monosaccharides (glucose and galactose). The activity of enzymes involved in galactose metabolism has repeatedly been found to be normal. The first manifestations of this syndrome are first recognized usually between 3 and 10 months of age when the children present with clinical signs of rickets, short stature (<31 percentile), dystrophy, polyuria and significant hepatomegaly. We report a case of FBS first detected during the neonatal period.
CASE REPORT
A male infant was born at 40 weeks of gestational age by spontaneous delivery, his birthweight was 3230 g and the perinatal period was normal. At 27 days of age, the infant was admitted to the hospital because of recurrent vomiting and fever. Physical examination did not show clinical evidence of other disease with the exception of distended abdomen and mild hepatomegaly; his growth parameters were within normal range. He was the first child of consanguineous Arabian parents and had a negative family history of disease.
Polyuria, fasting hypoglycemia and postprandial hyperglycemia were detected. Urine analysis showed pH 5 and presence of protein and glucose. The 24-hour urine samples showed glycosuria (20 g/ 24 hour), proteinuria (277 mg/24 hour), phosphaturia (47.5 mg/ kg/24 hour) and generalized aminoaciduria. The 24-hour creatinine clearance and urinary secretions of sodium and potassium were within normal values. Metabolic acidosis was not present. Urinary electrophoresis showed glomerular and tubular proteinuria; urinary b2-microglobuline was considerably raised (47,794 ng/ml, normal range 0 to 300). Serum alkaline phosphatase level was increased, the circulating level of parathyroid hormone and serum calcium were normal and phosphorus was mildly decreased (serum alkaline phosphatase (ALP) 4.768 U/l, normal range 164±68; parathyroid hormone (PTH) 71 pg/ml, normal range 9 to 78; calcium (Ca 2 þ ) 9.5 mg/ dl, normal range 8.4 to 11.6; phosphorus (P þ ) 3.7 mg/dl, normal range 4.5 to 6.5). Basal insulin was within normal range and plasmatic cortisol was normal. The infant was found to have elevated levels of transaminases.
Imaging studies failed to show evidence of skeletal rickets. Renal ultrasound evaluation was normal. Ophthalmologic slitlamp examination was negative for cystine crystal deposits.
Molecular genetic analysis showed homozygosity for mutation within the gene of the glucose transporter 2 (Glut 2), 1213 C>T.
DISCUSSION
The originality of this case is the timing of diagnosis in the neonatal period because of the early observation of polyuria and hyperglycemia. The incidence of FBS is not known; 109 cases from 88 families have been described worldwide so far. 2 To our knowledge, only three other cases of FBS have been reported that were recognized in the neonatal period. One of these was found to have high galactose levels in neonatal screening. 3 To confirm the diagnosis, we performed molecular genetic analysis. In 1997, Santer et al. described the basic defect of this disease when reporting homozygosity for mutations within the gene of the glucose transporter 2 (Glut 2) in four patients. These mutations represented the first detection of a congenital defect within a whole family of membrane proteins, the facilitative glucose transporters.
2 As in our case, the affected infants are frequently the products of a consanguineus parentage. 1 No specific therapy is available for this syndrome; only symptomatic replacement of water, electrolytes, vitamin 1a-OH-D3 and phosphate, restriction of galactose intake, a diabetes mellituslike diet and adequate caloric intake with a frequent small meals may improve growth. 4 Without oral phosphate and vitamin D supplementation severe hypophosphatemic rickets may occur in the first months of age. After initiation of frequent small meals and galactose-free-milk diet and pharmacological treatment with phosphate and vitamin D, our patient had clinical and metabolic improvement. At the age of 1 year his growth, clinical condition and metabolism of vitamin D are normal. Long-term prognosis is not known; in general, there is no progression to glomerular insufficiency 1 and no deterioration of tubular defects.
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